TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B	belantamab mafodotin-blmf Sensitive: B - Late Trials belantamab mafodotin-blmf Sensitive : B
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D	ACLX-001 Sensitive: D – Preclinical ACLX-001 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D	CC-93269 + CC-220 Sensitive: D – Preclinical CC-93269 + CC-220 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	CC-93269 + CC-92480 Sensitive: D – Preclinical CC-93269 + CC-92480 Sensitive : D	CC-93269 + CC-92480 Sensitive: D – Preclinical CC-93269 + CC-92480 Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	HDP-101 Sensitive: D – Preclinical HDP-101 Sensitive : D	HDP-101 Sensitive: D – Preclinical HDP-101 Sensitive : D
TNFRSF17 expression	Lymphoma	TNFRSF17 expression	Lymphoma	belantamab mafodotin-blmf Sensitive: D – Preclinical belantamab mafodotin-blmf Sensitive : D	belantamab mafodotin-blmf Sensitive: D – Preclinical belantamab mafodotin-blmf Sensitive : D
TNFRSF17 expression	Multiple Myeloma	TNFRSF17 expression	Multiple Myeloma	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D	JNJ-5322 Sensitive: D – Preclinical JNJ-5322 Sensitive : D

TNFRSF17 expression

Associations